Reports Summarize Chemotherapy Findings from Soochow University (Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news originating from Suzhou, People's Republic of China, by NewsRx correspondents, research stated, "In recent years, polymeric nanoparticles have appeared as a most viable and versatile delivery system for targeted cancer therapy. Various in vivo studies have demonstrated that virus-sized stealth particles are able to circulate for a prolonged time and preferentially accumulate in the tumor site via the enhanced permeability and retention (EPR) effect (so-called 'passive tumor-targeting')."
Our news journalists obtained a quote from the research from Soochow University, "The surface decoration of stealth nanoparticles by a specific tumor-homing ligand, such as antibody, antibody fragment, peptide, aptamer, polysaccharide, saccharide, folic acid, and so on, might further lead to increased retention and accumulation of nanoparticles in the tumor vasculature as well as selective and efficient internalization by target tumor cells (termed as 'active tumor-targeting'). Notably, these active targeting nanoparticulate drug formulations have shown improved, though to varying degrees, therapeutic performances in different tumor models as compared to their passive targeting counterparts. In addition to type of ligands, several other factors such as in vivo stability of nanoparticles, particle shape and size, and ligand density also play an important role in targeted cancer chemotherapy. In this review, concept and recent development of polymeric nanoparticles conjugated with specific targeting ligands, ranging from proteins (e.g., antibodies, antibody fragments, growth factors, and transferrin), peptides (e.g., cyclic RGD, octreotide, AP peptide, and tLyp-1 peptide), aptamers (e.g., A10 and AS1411), polysaccharides (e.g., hyaluronic acid), to small biomolecules (e.g., folic acid, galactose, bisphosphonates, and biotin), for active tumor-targeting drug delivery in vitro and in vivo are highlighted and discussed."
According to the news editors, the research concluded: "With promise to maximize therapeutic efficacy while minimizing systemic side effects, ligand-mediated active tumor-targeting treatment modality has become an emerging and indispensable platform for safe and efficient cancer therapy."
For more information on this research see: Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy. Biomacromolecules, 2014;15(6):1955-1969. Biomacromolecules can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Biomacromolecules - www.pubs.acs.org/journal/bomaf6)
The news correspondents report that additional information may be obtained from Y.A. Zhong, Soochow Univ, Jiangsu Key Lab Adv Funct Polymer Design & Applic, Coll Chem Chem Engn & Mat Sci, Suzhou 215123, People's Republic of China. Additional authors for this research include F.H. Meng, C. Deng and Z.Y. Zhong (see also Drugs and Therapies).
Keywords for this news article include: Asia, Antibodies, Suzhou, Cancer, Oncology, Peptides, Immunology, Proteomics, Chemotherapy, Nanoparticle, Blood Proteins, Nanotechnology, Immunoglobulins, Drugs and Therapies, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC